A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease

International Journal of Antimicrobial Agents

Volumn 36, Issue 1, 2010, Pages 79-83

  Olivieri, Bianca P ^a   Molina, Judith Tibisay ^a   de Castro, Solange L ^a   Pereira, Mirian Claudia ^a   Calvet, Claudia M ^a   Urbina, Julio A ^b   Araújo Jorge, Tania C ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Benznidazole; Heart; Immune response; Posaconazole; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; CD4 ANTIGEN; CD8 ANTIGEN; CREATINE KINASE MB; IMMUNOGLOBULIN G; POSACONAZOLE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CULTURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHAGAS DISEASE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SPLENOMEGALY; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TRYPANOSOMA CRUZI;

ANIMALS; ANTIPROTOZOAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; DISEASE MODELS, ANIMAL; FEMALE; HEART; HUMANS; MICE; MYOCARDIUM; NITROIMIDAZOLES; SURVIVAL ANALYSIS; TRIAZOLES; TRYPANOSOMA CRUZI;

EID: 77953021818     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.03.006     Document Type: Article

References (15)

1. Schofield C.J., Jannin J., Salvatella R. The future of Chagas disease control. Trends Parasitol 2006, 22:583-588.
2. Moncayo A., Silveira A.C. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009, 104(Suppl. 1):17-30.
3. Marin-Neto J.A., Cunha-Neto E., Maciel B.C., Simões M.V. Pathogenesis of chronic Chagas heart disease. Circulation 2007, 115:1109-1123.
4. Urbina J.A. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2009, Nov 10 [Epub ahead of print].
5. Viotti R., Vigliano C., Lococo B., Bertocchi G., Petti M., Alvarez M.G., et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006, 144:724-734.
6. Minoprio P. Parasite polyclonal activators: new targets for vaccination approaches?. Int J Parasitol 2001, 31:588-591.
7. + T-cell expansion and promotes resistance to reinfection. Antimicrob Agents Chemother 2002, 46:3790-3796.
8. Andrade S.G., Stocker-Guerret S., Pimentel A.S., Grimaud J.A. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Oswaldo Cruz 1991, 86:187-200.
9. Segura M.A., Molina de Raspi E., Basombrio M.A. Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment. Mem Inst Oswaldo Cruz 1994, 89:213-216.
10. Andrade S.G., Grimaud J.A., Stocker-Guerret S. Sequential changes of the connective matrix components of the myocardium (fibronectin and laminin) and evolution of cardiac fibrosis in mice infected with Trypanosoma cruzi. Am J Trop Med Hyg 1989, 40:252-260.
11. Souza A.P., Olivieri B.P., de Castro S.L., Araujo-Jorge T.C. Enzymatic markers of heart lesion in mice infected with Trypanosoma cruzi and submitted to benznidazole chemotherapy. Parasitol Res 2000, 86:800-808.
12. Ferraz M.L., Gazzinelli R.T., Alves R.O., Urbina J.A., Romanha A.J. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother 2007, 51:1359-1364.
13. + T central memory response in chronic Chagas disease. Nat Med 2008, 14:542-550.
14. + T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. Antimicrob Agents Chemother 2009, 53:174-179.
15. Tarleton R.L., Reithinger R., Urbina J.A., Kitron U., Gürtler R.E. The challenges of Chagas disease-grim outlook or glimmer of hope. PLoS Med 2007, 4:e332.